Paper Details

  1. Home
  2. Paper Details

Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone.

Author: AlcaláA, BuenoJ, DomingoA, FerránC, García-CondeJ, GiraltM, MontserratE, ParodyR, RubioD, SanzM A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

A study of 96 patients with advanced chronic lymphocytic leukemia (CLL) compared two chemotherapy regimens: chlorambucil plus prednisone (CLR+PDN) and cyclophosphamide, vincristine, and prednisone (COP). CLR+PDN resulted in a higher response rate (59%) compared to COP (31%), but survival was similar between the groups. Patients who had received prior treatment had lower response rates compared to those who had not received prior treatment. Patients achieving complete or good partial remission had longer survival compared to those with poor remission or no response. These findings suggest that CLR+PDN may be a more effective initial treatment for CLL, but further research is needed to optimize treatment strategies based on individual patient factors.
Paper Details　
Original Abstract of the Article :
Ninety-six patients with advanced chronic lymphocytic leukemia (CLL) (Stage C; anemia and/or thrombocytopenia of nonimmune origin) were randomized to receive either chlorambucil (CLR) (0.4 mg/kg orally, day 6) plus prednisone (PDN) (60 mg/m2 orally, days 1-5) every 2 weeks or cyclophosphamide (600 m...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/1097-0142(19851115)56:10<2369::aid-cncr2820561004>3.0.co;2-n

データ提供：米国国立医学図書館（NLM）

Treatment of Chronic Lymphocytic Leukemia: Navigating the Desert of Disease

Chronic lymphocytic leukemia (CLL) is a complex and challenging disease, requiring careful and personalized treatment strategies. This study compares the effectiveness of two treatment regimens for advanced CLL: chlorambucil plus prednisone (CLR + PDN) and cyclophosphamide, vincristine, and prednisone (COP). The authors, like skilled desert navigators, examine the efficacy and safety of these regimens, providing valuable insights for oncologists and patients alike. Their findings highlight the importance of considering individual patient factors and the need for ongoing research to optimize CLL treatment.

A Tailored Approach: Choosing the Right Path Through the Desert of CLL

The study reveals that CLR + PDN is more effective than COP in inducing remission in patients with advanced CLL. This is like choosing the right path through a vast and unforgiving desert, ensuring that travelers reach their destination with greater safety and success. The authors emphasize the importance of considering individual patient characteristics and the need for ongoing research to identify the most effective treatment strategies for CLL.

A Beacon of Hope: Finding New Pathways for Treating CLL

This research provides valuable insights into the treatment of advanced CLL, highlighting the importance of personalized medicine and the need for continued research to develop more effective therapies. It serves as a beacon of hope for patients facing the challenges of this disease, reminding us that the desert of CLL can be navigated with greater success through ongoing innovation and a commitment to personalized care.

Dr.Camel's Conclusion

This study is like finding a new oasis in the desert of chronic lymphocytic leukemia research. It highlights the importance of personalized medicine in treating this challenging disease, recognizing that each patient's journey is unique. By considering individual patient factors and exploring new treatment options, we can navigate the complexities of CLL with greater effectiveness and compassion, ultimately leading to better outcomes for patients.

Date :
  1. Date Completed 1985-11-21
  2. Date Revised 2019-06-19
Further Info :

Pubmed ID

3899346

DOI: Digital Object Identifier

10.1002/1097-0142(19851115)56:10<2369::aid-cncr2820561004>3.0.co;2-n

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.